GlassScriptPhysician profile
Warda Niaz
NPI 1184090656
$7,927.60
in general payments reported to CMS, 2019-2025
36 companies · $69.89 in 2025
The $69.89 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $477 · 2021: $2,178 · 2022: $1,681 · 2023: $2,412 · 2024: $1,110 · 2025: $69.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,305.50 | 2020-2024 | Mounjaro, Jardiance, Humulin |
| Dexcom, INC. | $973.42 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $863.45 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $514.78 | 2020-2024 | |
| Mannkind Corporation | $489.94 | 2021-2024 | Afrezza |
| Antares Pharma, INC. | $327.95 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $304.68 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.88 | 2020-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $293.65 | 2020-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $264.57 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $254.50 | 2021-2024 | |
| Amgen INC. | $222.92 | 2020-2024 | Prolia, Evenity, Repatha |
| Amarin Pharma, INC. | $221.11 | 2020-2021 | |
| Medtronic, INC. | $195.52 | 2021-2024 | Minimed 780g |
| Abbott Laboratories | $187.22 | 2021-2024 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $148.82 | 2021-2024 | Tirosint, Licart, Licart |
| Radius Health, INC. | $142.36 | 2023-2024 | Tymlos |
| Beta Bionics, INC. | $134.17 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $112.45 | 2021-2024 | |
| Amryt Pharma Holdings LTD | $104.35 | 2023 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $97.38 | 2023-2024 | |
| Insulet Corporation | $71.07 | 2021-2023 | Omnipod |
| Horizon Therapeutics Plc | $60.43 | 2022 | |
| Amneal Pharmaceuticals LLC | $55.08 | 2023-2024 | Unithroid |
| Tandem Diabetes Care, INC. | $39.48 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $29.70 | 2020-2021 | |
| Pfizer INC. | $29.63 | 2022 | |
| Medtronic Minimed, INC. | $27.75 | 2020 | |
| Esperion Therapeutics, INC. | $25.98 | 2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $23.61 | 2020-2021 | |
| Kyowa Kirin, INC. | $22.19 | 2023 | Crysvita |
| Halozyme INC | $19.20 | 2023 | |
| Eisai INC. | $18.57 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.87 | 2023 | Strensiq |
| Rhythm Pharmaceuticals, INC. | $15.33 | 2022 | |
| Vivus LLC | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warda Niaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.